Managed Access AgreementManaged Access Agreement • February 14th, 2019Contract TypeManaged Access AgreementFiledFebruary 14th, 2019Tisagenlecleucel for treating relapsed or refractory diffuse large B- cell lymphoma after 2 or more systemic therapies [ID1166]
Tisagenlecleucel for treating relapsed or refractory diffuse large B- cell lymphoma after 2 or more systemic therapies [ID1166]